Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.
about
TCEAL7, a putative tumor suppressor gene, negatively regulates NF-kappaB pathwayGlycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to-Mesenchymal Transition?Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategiesSystems biology of cisplatin resistance: past, present and futurePhase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.High expression of MnSOD promotes survival of circulating breast cancer cells and increases their resistance to doxorubicinOncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinomaBIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cellsGlobal analysis of DNA methylation by Methyl-Capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cellAlteration of cellular behavior and response to PI3K pathway inhibition by culture in 3D collagen gelsCombination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expressionControl of cellular Bcl-xL levels by deamidation-regulated degradationExploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomasThe Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian CancerAntagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells.Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.NOXA-induced alterations in the Bax/Smac axis enhance sensitivity of ovarian cancer cells to cisplatinBcl-xL overexpression and its association with the progress of tongue carcinoma.Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines.A seven-gene prognostic model for platinum-treated ovarian carcinomas.Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101.DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell linesThe p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1Dynamic Bcl-xL (S49) and (S62) Phosphorylation/Dephosphorylation during Mitosis Prevents Chromosome Instability and Aneuploidy in Normal Human Diploid FibroblastsEmetine regulates the alternative splicing of Bcl-x through a protein phosphatase 1-dependent mechanism.Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling.AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer.Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinomaMolecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy.Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cellsObatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cellsMismatch repair protein deficiency compromises cisplatin-induced apoptotic signaling.Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.Alpha-tocopheryl succinate potentiates the paclitaxel-induced apoptosis through enforced caspase 8 activation in human H460 lung cancer cells.ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP.New strategies for the treatment of ovarian cancer.
P2860
Q24336598-FD2E0CEB-E624-485E-80CA-C5664121CB9BQ26742115-81713296-1071-4E6A-92C2-FF0B7AE55C75Q26750639-5EC07770-8AFF-4A72-A490-D124CA9B3141Q26863585-0FB437F9-4BEB-4A83-B171-D1BD4287A229Q27851478-A6FA6708-7132-49EF-A96C-9228CFAA832FQ28468665-0F9A6963-DA6E-4351-A3FD-96A44A78BD65Q28474516-8D84F3F7-7D77-46BA-B7F8-FA3F76D59D13Q28478390-1D7A501B-95D5-4B5C-976B-DD81EF1B08F1Q28478564-BAA1CECC-C7E3-46EA-A782-49C3D9CB674DQ28484532-01E54935-905D-49B1-AA84-11E916727837Q28485457-08D550CA-0348-4024-B14B-63EB10816F0EQ28534291-345AB103-30D4-421C-AA0C-C9F04DEDD2FAQ28538327-2523EE25-34BC-4D65-91CD-7EE6EEEA7F9CQ28833833-F82416C1-080C-487D-9492-9E1F494D0724Q33431526-638774D4-4C9B-484D-AB36-EB0E7532824BQ33955266-8118BC5D-DBB2-48F8-8854-A1A9F78CD6EBQ33980773-EBFDDAD3-A72E-4417-BC59-163E401D7AAEQ34086841-E9640B25-2979-4E3F-B587-DE6401B90C39Q34166257-9F050DC6-9914-461B-B5F1-BC59190C588DQ34270948-D84F8850-08EC-40C8-92D3-CA52A3695234Q34732893-22C9BC94-3D47-4AE3-8C60-951A5A5211C5Q35093687-87C4E119-F320-48F4-882A-251EEFB0A0F5Q35125629-C9140937-31C4-49B8-B0F4-C719472584D6Q35643843-28DD30E4-EC1D-4F70-BAE1-8193AB13ED8EQ35768464-C615AABF-210B-469B-AC68-F68C4839B077Q35876786-8B4547CD-CAE5-486F-88E6-A56B7BFB5486Q36072488-5819F7B8-70F8-4448-BF6D-AF0706CE599DQ36344912-7BD3692F-FE81-4142-AC67-1450AD271710Q36825646-1C372DEE-ECF8-48B9-9424-63EF33092C3AQ36919815-24B39991-98B2-4260-81A7-5CF7362E5F59Q36924759-C47A4102-84FA-41A4-9A45-1C3563582362Q36953849-0DECBB42-1FED-4327-BC91-67CB4E93FA04Q36962681-C961BF63-B6D4-429B-BF7B-158326088C0BQ37046690-54684A34-2A14-446E-A2BC-CC826257246BQ37194167-3F9E7422-492A-4CF3-B386-64E94FE28E57Q37328373-AE2FA2D9-0DC9-4191-8584-F454971CCE6EQ37411205-41DBA838-AFBE-4D10-92D2-237E02A179B7Q37712188-015D95CE-E813-46BD-97E4-5BFC57366C5FQ37718693-7D71E461-255B-42B3-8B67-9EFFAF7A86EAQ38180769-C592C3E1-86CF-437F-9F76-606D7BA48F35
P2860
Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Expression of Bcl-xL in ovaria ...... istance and recurrent disease.
@en
type
label
Expression of Bcl-xL in ovaria ...... istance and recurrent disease.
@en
prefLabel
Expression of Bcl-xL in ovaria ...... istance and recurrent disease.
@en
P2093
P1433
P1476
Expression of Bcl-xL in ovaria ...... istance and recurrent disease.
@en
P2093
J Rebecca Liu
Jennifer Williams
Kent A Griffith
Milheon Choi
Peter C Lucas
Sarah Fogoros
Yuan Yuan Hu
P304
P356
10.1016/J.YGYNO.2004.10.026
P407
P577
2005-02-01T00:00:00Z